Edgar Filing: MAIDA ANTHONY E III - Form 4

MAIDA AN Form 4	NTHONY E III										
November (02, 2012										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								MMISSION	OMB APPROVAL		
Washington, D.C. 20549								OMB Number:	3235-0287		
	Check this box if no longer CTA TED (ENTER OF CHANCES IN DEDUCTAL OWNERSHIP OF							EDSILIDAE	Expires:	January 31, 2005	
Section	subject to Section 16. Form 4 or					LKSHIP OF	Estimated average burden hours per response 0.				
Form 5 obligation may corn See Insta 1(b).	ons Section 17(a) of the I	Public U	tility Ho	lding Co	mpar	•	Act of 1934, 1935 or Section			
(Print or Type	Responses)										
MAIDA ANTHONY E III Symbol SPECT				I				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (A	Middle)	3. Date of Earliest Transaction (Month/Day/Year)			_X_ Director 10% Owner Officer (give title Other (specify					
11500 S. E. 240	ASTERN AVE., S	SUITE	11/01/2	-			ł	pelow)	below)		
				onth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
HENDERS	ON, NV 89052						-	Form filed by Me Person			
(City)	(State)	(Zip)	Tab	le I - Non	-Derivative	e Secu	rities Acqu	ired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, i any (Month/Day/Year)		Date, if	Code (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following	OwnershipIndireForm:BenerDirect (D)Owneror Indirect(Instr	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				(A) or Code V Amount (D) Price			Price	Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)		
Common Stock	11/01/2012			M	3,300	A	\$ 2.55	5,550	D		
Common Stock	11/01/2012			S <u>(1)</u>	3,300	D	\$ 11.0976 (2)	2,250	D		
Common Stock	11/01/2012			М	1,700	А	\$ 4.26	3,950	D		

\$

(3)

11.0688 2,250

D

1,700 D

S(1)

Common

Stock

11/01/2012

Edgar Filing: MAIDA ANTHONY E III - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option Exercise (Right to Buy)	\$ 2.55	11/01/2012		М	3,300	03/25/2009 <u>(4)</u>	03/25/2018	Common Stock	3,300
Stock Option Exercise (Right to Buy)	\$ 4.26	11/01/2012		М	1,700	01/01/2009 <u>(5)</u>	12/06/2015	Common Stock	1,700

Reporting Owners

Reporting Owner Name / Address		Relationsh					
	Director	10% Owner	Officer	Other			
MAIDA ANTHONY E III 11500 S. EASTERN AVE. SUITE 240 HENDERSON, NV 89052	Х						
Signatures							
/s/ Brett L. Scott, attorney-in-fa Maida	thony E.		11/02/2012				
<u>**</u> Signature of Reporting			Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2012.

(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$11.04 to \$11.13, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$11.04 to \$11.18, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum

- (3) The reporting person undertakes to provide to spectrum Pharmaceuticals, inc., any security holder of spectrum Pharmaceuticals, inc., and security holder of spectrum Pharmaceuticals, inc., any security holder of spectrum Pharmaceuticals, inc., and security holder of spe
- (4) The stock option, representing the right to purchase a total of 30,000 shares of common stock, was granted on March 25, 2008. The stock option became exercisable as to 15,000 shares on March 25, 2008 and 15,000 shares on March 25, 2009.

The stock option, representing the right to purchase a total of 15,000 shares of common stock, was granted on December 6, 2005. The (5) stock option became exercisable as to 3,750 shares on January 1, 2006, 3,750 shares on January 1, 2007, 3,750 shares on January 1, 2008, and 3,750 shares on January 1, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.